TSBX vs. MGX, ZURA, ELEV, IVVD, CHRS, IPHA, GLUE, SCLX, CMPX, and CGEN
Should you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Metagenomi (MGX), Zura Bio (ZURA), Elevation Oncology (ELEV), Invivyd (IVVD), Coherus BioSciences (CHRS), Innate Pharma (IPHA), Monte Rosa Therapeutics (GLUE), Scilex (SCLX), Compass Therapeutics (CMPX), and Compugen (CGEN). These companies are all part of the "biological products, except diagnostic" industry.
Metagenomi (NASDAQ:MGX) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
Turnstone Biologics has lower revenue, but higher earnings than Metagenomi.
Metagenomi received 7 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 90.00% of users gave Metagenomi an outperform vote while only 50.00% of users gave Turnstone Biologics an outperform vote.
52.5% of Turnstone Biologics shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Metagenomi currently has a consensus price target of $17.83, suggesting a potential upside of 179.52%. Turnstone Biologics has a consensus price target of $19.00, suggesting a potential upside of 627.97%. Given Metagenomi's higher probable upside, analysts clearly believe Turnstone Biologics is more favorable than Metagenomi.
In the previous week, Metagenomi and Metagenomi both had 3 articles in the media. Turnstone Biologics' average media sentiment score of 0.72 beat Metagenomi's score of 0.39 indicating that Metagenomi is being referred to more favorably in the media.
Turnstone Biologics' return on equity of 0.00% beat Metagenomi's return on equity.
Summary
Metagenomi beats Turnstone Biologics on 9 of the 13 factors compared between the two stocks.
Get Turnstone Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Turnstone Biologics Competitors List
Related Companies and Tools
